A trial looking at low intensity stem cell transplant after chemotherapy for acute myeloid leukaemia and high risk myelodysplastic syndrome (MUNICH)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Acute leukaemia
Acute myeloid leukaemia (AML)
Blood cancers
Myelodysplastic syndrome (MDS)




Phase 2

This trial is looking at having a reduced intensity stem cell transplant straight after chemotherapy for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome Open a glossary item (MDS). This trial is for people with AML or high risk MDS that has not responded to treatment or come back after treatment.

Doctors can treat AML and high risk MDS with chemotherapy and a stem cell transplant. They give chemotherapy first to try and get rid of all the cancerous or abnormal cells. After you recover from chemotherapy you have a test to see how well it worked. If your test shows no sign (or nearly no sign) of cancer or abnormal cells, you may have a stem cell transplant. The transplant can be several weeks after chemotherapy. This means having 2 periods of time in hospital, one for chemotherapy and one for the transplant.

The researchers are looking at giving the transplant 3 days after chemotherapy. They are using lower doses of treatment than people usually have before a stem cell transplant. This is called a reduced intensity transplant. This would mean having only one period of time in hospital.

We know from research that reduced intensity transplant can help people whose AML or high risk MDS did not respond to treatment or came back after treatment. We also know that these people could benefit from having the transplant straight after chemotherapy.

The aims of this trial are to find out

  • How well having a stem cell transplant straight after chemotherapy works for people with AML and high risk MDS that has not responded to treatment or come back after treatment
  • How long they need to stay in hospital
  • What the side effects are

Who can enter

You can enter this trial if you

  • Have acute myeloid leukaemia, or high risk myelodysplastic syndrome that has not responded to treatment or has come back after treatment
  • Have recovered from side effects of treatment you have already had
  • Can look after yourself and are up and about for more than half the day (performance status 0, 1, 2)
  • Are willing to use reliable contraception if there is a chance you or your partner could become pregnant
  • Are 18 to 60 years old

You cannot enter this trial if you

  • Have had a cancer treatment in the last 14 days – apart from hydroxycarbamide or low dose cytarabine
  • Had surgery in the last 21 days
  • Are taking medication as part of another clinical trial
  • Have a serious problem with your heart
  • Have had another cancer, unless it was successfully treated and there has been no sign of it (complete remission Open a glossary item) in the last 5 years – you may join the trial if you have in situ carcinoma of the cervix and basal or squamous cell cancer of the skin that has been successfully treated
  • Have another medical condition that could affect you taking part in the trial


Trial design

This is a phase 2 trial. It will recruit between 90 and 95 people in the UK.

Everyone will have chemotherapy before a reduced intensity stem cell transplant.

You have chemotherapy though a drip into the vein over 14 days. Some days you will have more than one drug. You will have

After a break of 3 days you have your stem cell transplant.

You will have some other drugs after your transplant and your doctor will tell you about these.

Hospital visits

You will see the doctor and have some tests before starting treatment. These include

  • A physical examination
  • Blood tests
  • Tests to see how your lungs work (Lung function tests Open a glossary item)
  • Heart scan (Echocardiogram Open a glossary item)
  • Bone marrow test

Even though this trial is looking at reduced intensity transplants, this is still quite intensive treatment. You will be in hospital between 4 and 6 weeks.

When you go home you will have to go back to the hospital quite often. This will be at least every week at the beginning. And then at longer times as your doctor feels is suitable.

You have a bone marrow test 1month and 3 months after your treatment.

Side effects

The common side effects of the chemotherapy used in this trial are

The side effects of a stem cell transplant can include

You can find more information about stem cell transplants, daunorubicin, cyclophosphamide, fludarabine and cytarabine on CancerHelp UK.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr James Cavenagh

Supported by

Barts Health NHS Trust
Experimental Cancer Medicine Centre (ECMC)
Queen Mary University of London

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 2591

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page